Multiple System Atrophy (MSA) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Multiple System Atrophy (MSA) Market is Segmented By Subtype (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Multiple System Atrophy (MSA) Market Size
Market Size in USD
CAGR4.5%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 4.5% |
| Market Concentration | High |
| Major Players | Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc. |
please let us know !
Multiple System Atrophy (MSA) Market Analysis
The Multiple System Atrophy (MSA) Market is estimated to be valued at USD 148.1 Mn in 2024 and is expected to reach USD 202.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
The MSA market is expected to witness steady growth over the forecast period. This can be attributed to the increasing diagnosis rate of MSA and growing research activities for development of effective treatments. Currently, there is no cure for MSA and only symptomatic treatments are available which provide modest benefits. Thus, drug manufacturers are focusing on developing new disease-modifying treatments such as neuroprotective agents and antioxidants. Furthermore, rising healthcare expenditure in major markets and expansion of clinical trials for pipeline drugs are some other factors expected to drive the demand for MSA treatment and thereby support the growth of the market during the forecast period.